Table 1.

Baseline characteristics of patients treated with afatinib and cetuximab concurrently

T790M Mutation status (available for 124 patients)
TotalT790M+T790M
Patients, n (%)126 (100)71 (100)53 (100)
Median age at baseline, years (range)59 (31–82)58 (31–82)60 (40–79)
Gender, n (%)
 Male33 (26)20 (28)12 (23)
 Female93 (74)51 (72)41 (77)
Race, n (%)
 American Indian/ Alaska Native2 (2)1 (1)1 (2)
 Asian19 (15)12 (17)7 (13)
 Black/African American10 (8)7 (10)3 (6)
 White95 (75)51 (72)42 (79)
Baseline ECOG PS, n (%)
 027 (21)17 (24)10 (19)
 ≥199 (79)54 (76)43 (81)
Median time since diagnosisa, years (range)2 (0.5b–11)2 (0.5b–11)2 (1–7)
Median duration of prior EGFR TKI treatmentc, years (range)1(0–7)2 (0–7)1(0–6)
Prior chemotherapy, n (%)
 0–1 line61 (48)32 (45)28 (53)
 ≥2 lines65 (52)39 (55)25 (47)
EGFR-mutation status, n
 Del 19+784434
 L858R+412415
 Otherd422
EGFR wild-typee312
  • aData available for 121, 69, and 50 patients, respectively.

  • b4.5 months.

  • cMaximum duration if patients received more than 1 prior EGFR TKI regimen.

  • dIncludes G719S, G719A, G719C, S768I, and L861Q.

  • ePatients enrolled into the dose-finding phase were not required to be EGFR mutation–positive; patients enrolled following identification of the MTD were required to be EGFR mutation–positive.

    Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.